LIVN LivaNova Plc

LivaNova Announces Thad Huston as Chief Financial Officer

LONDON--(BUSINESS WIRE)--

LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced Thad Huston will join the Company as its new Chief Financial Officer (CFO), effective May 20, 2017. LivaNova’s former CFO, Vivid Sehgal, is coordinating with Huston to ensure an orderly transition. Huston will report directly to Damien McDonald, Chief Executive Officer (CEO).

Huston is a highly strategic global finance executive who joins LivaNova after more than 25 years at Johnson & Johnson (J&J), having most recently served as Group Chief Financial Officer, Medical Devices. While at J&J, Huston was pivotal in accelerating the growth for many of its divisions through focused strategies, calculated investments in innovation and streamlined productivity.

“I am pleased to welcome Thad Huston to LivaNova and to our Executive Leadership Team as our new CFO,” said Damien McDonald, LivaNova CEO. “Thad is equipped with a strong healthcare and medical device background, coupled with the financial acumen and acuity to enhance our strategic growth plans. I look forward to working together to drive performance, build our pipeline and expand our portfolio in a sustainable manner.”

During his tenure at J&J, Huston held various senior roles, including: President of J&J’s Xian-Janssen Pharmaceuticals division in China; Vice President – Finance, Chief Financial Officer and Chief Operations Officer in J&J Pharmaceutical Research and Development; as well as Vice President – Finance and Chief Financial Officer at Ortho-McNeil Pharmaceuticals. Prior to this, he held senior financial roles at various J&J locations in the U.S., China, Belgium, Russia and Hungary.

“I am eager to join the exceptional team at LivaNova,” said Huston. “We share a passion for making a difference in patients’ lives, while focusing on growth that will lead us to even greater success as a company.”

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.

For more information, please visit www.LivaNova.com.

EN
16/05/2017

Underlying

LIVNLivaNova Plc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LivaNova Plc

 PRESS RELEASE
Free
LIVN LIVANOVA PLC

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 202...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $321.8 million increased 3.8% on a reported basis, 4.7% on a constant-currency basis, and 6.8% on an organic basis as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share of $1.02 and adjusted diluted earnings per share of $0.81 Full-year 2024 revenue of $1.25 billion increased 8.7% on a reported bas...

February 25, 2025 1 EN
 PRESS RELEASE
Free
LIVN LIVANOVA PLC

LivaNova to Present at the Barclays Global Healthcare Conference

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 2:00 p.m. Eastern Time on Tuesday, March 11. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay will be available on th...

February 21, 2025 1 EN
 PRESS RELEASE
Free
LIVN LIVANOVA PLC

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call. The audiocast will be accessible at . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial (if dialing from within the U.S.) or (if dial...

January 21, 2025 1 EN
 PRESS RELEASE
Free
LIVN LIVANOVA PLC

LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. “Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management,” Makatsaria said. “I look forward to collaborating with Natalia to further strengt...

January 6, 2025 1 EN
 PRESS RELEASE
Free
LIVN LIVANOVA PLC

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS The...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the . The researchers evaluated the safety and efficacy of LivaNova’s VNS Therapy™ System and its effectiveness on quality of life and daily function in this population of patients with treatment-resistant unipolar depression. Overall, the articles concluded that active VNS Therapy, as compared with a no-stimulation control (or sham VNS Therapy), safely and effective...

December 18, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch